share_log

Guggenheim Reiterates Buy on ANI Pharmaceuticals, Maintains $72 Price Target

Benzinga ·  Oct 19, 2023 13:39

Guggenheim analyst Vamil Divan reiterates ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and maintains $72 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment